Skip to main content
Clinical Trials/NCT02619383
NCT02619383
Completed
Phase 1

Hyperbaric Oxygen Can Improve Erectile Dysfunction and Induce Penile Angiogenesis

Assaf-Harofeh Medical Center1 site in 1 country37 target enrollmentJune 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Erectile Dysfunction
Sponsor
Assaf-Harofeh Medical Center
Enrollment
37
Locations
1
Primary Endpoint
Sexual function
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Recent studies have shown that hyperbaric oxygen therapy (HBOT) can induce angiogenesis and improve impaired organ function. HBOT was also recently suggested as a possible therapy for ED due to surgical injuries. However, the effect of HBOT on non-surgical related ED has not been investigated to date.

The objective in this study was to assess the effect of HBOT on patients with ED by means of sexual function questionnaires and novel imaging techniques.

Detailed Description

A prospective analysis of men, age 18 years or older, with a clinical diagnosis of erectile dysfunction, reporting decreased and weakened nocturnal penile tumescence of six months duration or longer. Patients were treated at The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression. Sexual function Efficacy of the treatment was assessed using the International Index of Erectile Function (IIEF) questionnaire which was filled by all patients at baseline and within 2 weeks of the last HBOT session. In addition, assessing efficacy was the global efficacy question (GEQ) ("Did the treatment improve your erections?"), with a response of yes or no. Six patients underwent two MRI scans 1-2 weeks prior to and after HBOT. Imaging was conducted in using a 3Tesla system (MAGNETOM Skyra, Siemens Medical Solutions, , Germany). The MRI protocol included anatomic T1 and T2 sequences and DCE. The MRI DCE sequence parameters are detailed in supplementary section.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
May 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Assaf Harofeh MC

Dr. Shai Efrati

Assaf-Harofeh Medical Center

Eligibility Criteria

Inclusion Criteria

  • age 18 years or older
  • clinical diagnosis of erectile dysfunction
  • reporting decreased and weakened nocturnal penile tumescence of six months duration or longer

Exclusion Criteria

  • penile anatomical defects,
  • any active or history of malignancy including prostate cancer
  • spinal cord injury
  • any major psychiatric disorder uncontrolled with treatment
  • claustrophobia
  • chronic lung disease
  • chronic middle ear or sinus diseases.

Outcomes

Primary Outcomes

Sexual function

Time Frame: 3 months

global efficacy question (GEQ) ("Did the treatment improve your erections?"), with a response of yes or no.

Secondary Outcomes

  • Imaging of penile perfusion(3 months)
  • Adverse events(3 months)

Study Sites (1)

Loading locations...

Similar Trials